依洛妥珠单抗 T35386

Product Introduction
Bioactivity


英文名: Elotuzumab

描述: Elotuzumab(HuLuc 63) (anti-SLAMF7) 是一种靶向 SLAMF7 受体的单克隆抗体。Elotuzumab (anti-SLAMF7) 是一种直接激活NK细胞并诱导抗体依赖性细胞毒性的化合物，可联合来那度胺和地塞米松 （Ld） 用于治疗多发性骨髓瘤。

体内活性: Elotuzumab (anti-SLAMF7) was given at 10 mg/kg weekly for the first two treatment cycles (28 days/cycle), followed by 10 mg/kg every other week for all subsequent cycles. Four different Elotuzumab (anti-SLAMF7) combination therapies were administered: 1) Elotuzumab (anti-SLAMF7) and dexamethasone 2) Elotuzumab (anti-SLAMF7), lenalidomide and dexamethasone 3) Elotuzumab (anti-SLAMF7), pomalidomide and dexamethasone and 4) Elotuzumab (anti-SLAMF7), carfilzomib, pomalidomide, and dexamethasone. We found that regardless of Elotuzumab (anti-SLAMF7) combination therapy, all patients treated showed decreased phosphorus levels after initiating Elotuzumab (anti-SLAMF7) treatment with reductions ranging from 12.5% to 44.1% below baseline. Six participants (67%) demonstrated average serum phosphorus at or below 2.5 mg/dL after starting Elotuzumab (anti-SLAMF7) therapy.[2]

存储条件: store at low temperaturestore at -20°C

关键字: PDL-063 | PDL063 | Elotuzumab | BMS-901608 | anti-SLAMF7 | BMS901608

依洛妥珠单抗 T35386信息由TargetMol中国为您提供，如您想了解更多关于依洛妥珠单抗 T35386报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途